DNA damage accumulation in dopaminergic neurons is a central pathological feature in Parkinson's disease. The high metabolic activity of these neurons, combined with mitochondrial dysfunction and oxidative stress, creates a perfect storm for genomic instability. Evidence shows that DNA repair pathways are impaired in PD patients, and enhancing DNA repair capacity represents a promising therapeutic strategy.
This page catalogs companies developing DNA damage repair therapies specifically for Parkinson's disease, including:
- PARP inhibitors for neuroprotection
- NAD+ precursors to support DNA repair enzymes
- Direct DNA repair enzyme replacement
- Genome maintenance and chromatin remodeling approaches
¶ PARP Inhibition and NAD+ Restoration
Poly(ADP-ribose) polymerases (PARPs) are activated by DNA damage to facilitate repair. However, excessive PARP activation depletes cellular NAD+ and ATP, leading to cell death (parthanatos). PARP inhibition protects neurons while preserving DNA repair capacity. Additionally, NAD+ precursors like NMN and NR boost SIRT1 activity and DNA repair capacity.
The base excision repair (BER) pathway is particularly important for repairing oxidative DNA damage (8-oxoguanine), which accumulates in PD brains. Enhancing BER enzymes like OGG1, APE1, and polymerase β could prevent mutation accumulation.
Transcription-coupled NER is crucial for repairing DNA lesions that block RNA polymerase II. Defects in this pathway contribute to neuronal dysfunction.
- Focus: PARP inhibition and cellular energy restoration
- Lead Candidate: LB-1 (NAD+ booster + PARP inhibitor combination)
- Indication: Parkinson's disease
- Stage: Phase 2
- Mechanism: Dual-action approach combining NAD+ restoration with PARP inhibition to prevent parthanatos
- Notes: Founded by David Sinclair, spinout from Harvard/Sinclair Lab
- Page: Life Biosciences
- Focus: NAD+ precursor supplementation
- Lead Candidate: NR (Nicotinamide Riboside)
- Indication: Parkinson's disease (preclinical)
- Stage: Preclinical/Phase 1
- Mechanism: NAD+ precursor to boost SIRT1 activity and enhance DNA repair capacity
- Notes: Consumer health division sells Tru Niagen, investigating therapeutic applications
- Page: ChromaDex
- Focus: SIRT1 activation through novel sulfonamides
- Lead Candidate: SRT2104 (SRT-2183)
- Indication: Parkinson's disease
- Stage: Phase 1
- Mechanism: SIRT1 activator to enhance DNA repair and mitochondrial function
- Notes: UK-based, focused on SIRT1 modulation for neurodegeneration
- Page: Evgen Pharma
- Focus: Mitochondrial DNA repair
- Lead Candidate: CT-001 (mitochondria-targeted DNA repair enzyme)
- Indication: Parkinson's disease
- Stage: Preclinical
- Mechanism: Mitochondria-targeted delivery of DNA repair enzymes to address mtDNA damage
- Notes: Novel approach targeting mitochondrial genome specifically
- Focus: PINK1-PARKIN pathway and mitochondrial quality control
- Lead Candidate: NPT-200
- Indication: Parkinson's disease
- Stage: Preclinical/IND-enabling
- Mechanism: While primarily focused on mitophagy, enhanced mitophagy reduces nuclear DNA damage accumulation from mitochondrial ROS
- Notes: Joint venture between Celgene/ BMS and The Michael J. Fox Foundation
- Page: Napa Therapeutics
¶ Vandria SA
- Focus: Mitochondrial quality control
- Lead Candidate: VNA-100
- Indication: Parkinson's disease
- Stage: Preclinical/IND-enabling
- Mechanism: Mitophagy inducer that reduces secondary DNA damage from mitochondrial dysfunction
- Notes: Swiss-based, dual programs in AD and PD
- Page: Vandria SA
¶ Clinical Development Landscape
| Company |
Candidate |
Mechanism |
Stage |
Status |
| Life Biosciences |
LB-1 |
NAD+ + PARP inhibition |
Phase 2 |
Active |
| ChromaDex |
NR |
NAD+ precursor |
Preclinical |
Planning |
| Evgen Pharma |
SRT2104 |
SIRT1 activator |
Phase 1 |
Active |
| Cytochrome Therapeutics |
CT-001 |
mtDNA repair |
Preclinical |
IND-enabling |
| Napa Therapeutics |
NPT-200 |
Mitophagy inducer |
Preclinical |
IND-enabling |
| Vandria |
VNA-100 |
Mitophagy inducer |
Preclinical |
IND-enabling |
Pharmaceutical companies are developing small molecules that directly enhance DNA repair enzyme activity:
- OGG1 activators: Target 8-oxoguanine glycosylase to accelerate BER
- APE1 stabilizers: Enhance apurinic/apyrimidinic endonuclease activity
- Pol β modulators: Boost DNA polymerase β for efficient gap-filling
Gene therapy delivery of DNA repair genes:
- OGG1 gene delivery: Increase capacity to repair oxidative lesions
- APE1 gene delivery: Enhance repair of abasic sites
- SIRT1 overexpression: Epigenetic enhancement of DNA repair
Since senescent cells accumulate DNA damage and secrete pro-inflammatory factors:
- Combination approaches: Remove damaged neurons that cannot repair their DNA
- Senomorphic: Reduce SASP without eliminating senescent cells
¶ Challenges and Considerations
Most DNA repair-targeted small molecules must penetrate the BBB. Key considerations:
- Lipophilicity and polar surface area
- Active transport mechanisms
- Prodrug strategies for CNS delivery
PARP inhibition requires careful dosing:
- Too much PARP inhibition may impair legitimate DNA repair
- Optimal dosing balances neuroprotection with repair capacity
Clinical trials need biomarkers for:
- DNA damage markers (γH2AX foci, 8-oxodG in CSF)
- NAD+ levels in peripheral tissues as proxy
- Functional imaging of DNA repair capacity